Navigation Links
SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
Date:11/27/2012

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Morgan & Morgan announces an investigation into whether certain officers and directors of Vertex breached their fiduciary duties to VRTX shareholders in connection with Vertex's recent public acknowledgement that it made inaccurate disclosures about the Phase 2 clinical studies of VX-909 and Kalydeco, two experimental drugs in clinical trials.  No decision to file a lawsuit has been made.  If you are a current shareholder of Vertex Pharmaceuticals and are interested in learning more about our Vertex (VRTX) shareholder lawsuit investigation, please contact George Pressly, Esq. at 1 (800) 631-6234 or email George at info@morgansecuritieslaw.com.

On May 7, 2012, Vertex issued a press release claiming that patients who received VX-909 and Kalydeco during a phase 2 clinical trial showed significant improvement in their lung functions. Published reports state that between May 7, 2012 and May 25, 2012, certain Vertex officers and directors sold over $22 million of their personally owned shares. On May 29, 2012, Vertex acknowledged publicly that the results from its clinical trials were not as positive as previously indicated. On June 27, 2012 Vertex admitted that the May 7th statements were simply inaccurate.   Vertex's stock price declined significantly on the news.

About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities law, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:
Morgan & Morgan
Peter Safirstein, Esq.
Five Penn Plaza
23rd Floor
New York, NY  10001
1-800-631-6234
info@morgansecuritieslaw.com

 


'/>"/>
SOURCE Morgan & Morgan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Issues Letter to Shareholders
2. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
3. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
4. Ampios CEO and CSO Send Message to Shareholders
5. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
6. Sinovac Schedules 2012 Annual Meeting of Shareholders
7. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
8. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
9. Carl Icahn Issues Open Letter to Shareholders of Forest Laboratories
10. AMRI Renews Shareholder Rights Plan
11. AspenBio Pharma to Provide Shareholders with Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 2017 Summary This report provides ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... 2017 The presence of ... vendor landscape of the  Global Lap on Chips ... high degree of consolidation with the top 8 ... market in 2016. Among these enterprises Danaher Corporation, ... Laboratories enjoy dominance on account of extensive geographical ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of the "Ovarian ... offering. The latest research Ovarian Cancer Drugs Price Analysis ... global Ovarian Cancer market. The research answers the following questions: ... Ovarian Cancer and their clinical attributes? How are they positioned in the ...
Breaking Medicine Technology:
(Date:3/1/2017)... Park, N.C. (PRWEB) , ... March 01, 2017 ... ... collaboration to bring PurThread’s permanently embedded anti-odor solution to cotton knit and woven ... lend performance attributes while maintaining the luxurious look and feel of cotton. ...
(Date:3/1/2017)... ... March 01, 2017 , ... Breast Surgeon, Dr. Dennis Holmes ... early stage breast cancer and where it fits in the treatment paradigm at Susan ... Make .” The event brings together leading cancer and wellness experts to share the ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... NY & Greenwich, CT (PRWEB) , ... March 01, 2017 , ... ... runners, especially in the winter months when people don’t want to stop training to ... knees – and setting the treadmill to a small incline can help protect these ...
(Date:3/1/2017)... ... , ... “McFarnia”: a suspenseful tale of a father who vanishes without a ... disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a former Army man, ... a Chaplain with Transport for Christ at a truck stop in the Greensboro area. ...
Breaking Medicine News(10 mins):